sefulness of Add-on Therapy of Pegylated Interferon alfa2a with Nucleoside/nucleotide Analog Treatment for Patients with Hepatitis B Virus Infectio
Not Applicable
- Conditions
- Chronic Hepatitis B
- Registration Number
- JPRN-UMIN000032717
- Lead Sponsor
- Saitama Medical University, Department of Gastroenterology & Hepatology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 26
Inclusion Criteria
Not provided
Exclusion Criteria
Cirrhosis HCC During pregnancy Mental illness merger Minor
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary endpoint is achievement rate of discontinuation of NA until 5 years after add-on therapy.
- Secondary Outcome Measures
Name Time Method